Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0822 Long-term Extension in Postmenopausal Osteoporosis
CTR20150027Phase 3Suspended
- Sponsor
- Merck & Co.
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of odanacatib in osteoporosis, sponsored by Merck & Co.. Started Oct 2015; status: suspended.
02
Drugs
odanacatib
03
Conditions
osteoporosis
Beyond the preview
Go deeper on CTR20150027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150027.